


Anti-14-3-3eta Multiplex for Axial Spondyloarthritis

Bridging critical gaps in axial
spondyloarthritis diagnosis



augurex 

Anti-14-3-3eta Multiplex is the only biomarker for axSpA



What is Axial Spondyloarthritis?


Axial Spondyloarthritis (axSpA) is a chronic inflammatory disease affecting the spine and sacroiliac joints, causing pain, stiffness, and joint damage.

Burden of Diagnostic Delay


AxSpA imposes a significant burden on patients, impacting physical function, mental health, and work productivity. Diagnosis is often delayed by 7-10 years due to the absence of reliable biomarkers, with many cases misdiagnosed as chronic low back pain. Early detection is critical for preventing long-term damage and improving patient outcomes.¹




Average years diagnostic delay¹



Had trouble getting out of bed²



Were affected by some form of psychological distress²



Reported difficulty finding a job due to their disease²



What is Anti-14-3-3eta Multiplex?

Anti-14-3-3eta Multiplex ASRs represent a first-in-class diagnostic that detects autoantibodies against the normally intracellular 14-3-3eta protein, a well-established biomarker in autoimmune rheumatologic disorders.

How it works



This novel Luminex[®] assay aids in identifying axSpA early, enabling rheumatologists to administer the right treatment at the right time, and reducing the significant patient burden of diagnostic delay.

Anti-14-3-3eta Multiplex is highly sensitive and highly specific for early diagnosis of axSpA



Key Features of Anti-14-3-3eta Multiplex

- ③ **Early and Accurate Diagnosis:** Anti-14-3-3eta Multiplex is highly sensitive (76%) and highly specific (74%), enabling differentiation between axSpA and healthy controls.³
- ③ **Complements CRP:** Combined with CRP, the Anti-14-3-3eta Multiplex can identify 90% of axSpA patients, improving diagnostic accuracy.⁴
- ③ **HLA-B27 Independent:** Anti-14-3-3eta Multiplex provides diagnostic value even in patients who are negative for traditional markers like HLA-B27.⁴



Key Benefits of Anti-14-3-3eta Multiplex

- ③ **Streamlined Diagnostic Process:** Aids in the early and accurate diagnosis of axSpA, reducing the 7-10 year average time to diagnosis.
- ③ **Complementary to Imaging:** Offers diagnostic support alongside traditional imaging.
- ③ **Clinical Confidence:** Enables evidence-based decisions, leading to more timely and appropriate treatment plans.
- ③ **Improved Outcomes:** Anti-14-3-3eta Multiplex aids in earlier detection and intervention of axSpA, potentially preventing long-term spinal damage.

Anti-14-3-3eta Multiplex ASRs Available Nationwide in 2025



Anti-14-3-3eta Multiplex is now available for early access in Knoxville, Tennessee, through our partnership with New Day Diagnostics as a laboratory-developed test (LDT). To order a test, visit <https://newdaydiagnostics.com/anti-14-3-3-eta-multiplex/>.

Expanded national access through leading labs in 2025.

To stay informed about updates visit <https://augurex.com/axial-spondyloarthritis/>.

Test Ordering Information



Partner with Augurex

Join us in improving diagnostic options for axSpA. Contact us for more information on how to access Anti-14-3-3eta Multiplex and collaborate to expand testing availability.

Contact



www.augurex.com



+1604-674-8231



info@augurex.com

References

1. Poddubnyy D, Garrido-Cumbrera M, Sommerfleck F, et al. POS0689. Diagnostic delay in patients included in the International Map of Axial Spondyloarthritis: associations with geographic, socio-demographic and disease-related factors. *Annals of the Rheumatic Diseases*. 2023;82:628-629
2. The burden of axial spondyloarthritis: A global patient perspective. International Map of Axial Spondyloarthritis (IMAS) Report. 2024, Jan. <https://asif.info/imas/imas-global-report>
3. Marotta A, Maksymowych WP, Wichuk S, Sidhu N. P54 Novel Diagnostic 14-3-3 η Auto-Antibody Marker for Axial Spondyloarthritis: A Longitudinal Study. Fourteenth International Congress on Spondyloarthritis. *Clin Exp Rheumatol*. 2024.
4. Marotta A, Maksymowych WP, Wichuk S, Sidhu N. POS1094 Autoantibodies to 14-3-3 η in Axial Spondyloarthritis. *Annals of the Rheumatic Diseases*. 2024;83:892-893.